Opportunities for finding proper treatments for both solid tumors and onco-hematological malignancies have never been better. Breakthroughs such as CAR-T cell therapies, checkpoint inhibitors, and combination therapies are rapidly earning FDA approval. With nearly infinite options in specificity and design, many more immune-based therapies are entering the clinical research funnel.
Nonetheless, clinical trial challenges remain. Key drivers include toxicity management, efficacy analysis, and follow-up. Parameters such as tissue distribution, tumor addiction, and surface density must be considered in predicting safety profiles.
The problem of finding proper resources to accomplish your studies compounds these hurdles. With over 35 years of experience, Cerba Research is a leader in oncology clinical trials. Our global solutions comprise a wide range of assays required at various stages of your trial.
Cerba Research Oncology Trials
Reach out to our experts and discover how we can help you advance your clinical trialsContact Us